Peter Stegagno Biography and Net Worth

Chief Operation Officer of Sanuwave Health

Peter Stegagno joined SANUWAVE as Vice President, Operations in March 2006. Stegagno has nearly 30 years of experience in the medical device market, encompassing manufacturing, design and development, quality assurance and international, and domestic regulatory affairs. He has been instrumental in the development and deployment of international operational processes for leading medical device companies.

Prior to joining SANUWAVE, Stegagno served as Vice President of Quality and Regulatory Affairs for Elekta and director level roles in medical device companies including Genzyme Biosurgery. Before focusing on the medical field, he enjoyed a successful career in production roles in the space industry, including avionics guidance systems for military applications and control computers for the space shuttle. Stegagno graduated from Tufts University with a B.S. degree in Chemical Engineering.

What is Peter Stegagno's net worth?: The estimated net worth of Peter Stegagno is at least $68.88 thousand as of June 5th, 2025. Mr. Stegagno owns 2,032 shares of Sanuwave Health stock worth more than $68,885 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Stegagno may own. Learn More about Peter Stegagno's net worth.
How do I contact Peter Stegagno?: The corporate mailing address for Mr. Stegagno and other Sanuwave Health executives is 3360 MARTIN FARM RD, SUITE 100, SUWANEE, GA, 30024. Sanuwave Health can also be reached via phone at (770) 419-7525 and via email at [email protected]. Learn More on Peter Stegagno's contact information.
Has Peter Stegagno been buying or selling shares of Sanuwave Health?: Peter Stegagno has not been actively trading shares of Sanuwave Health during the last ninety days. Most recently, Peter Stegagno sold 1,862 shares of the business's stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $27.71, for a transaction totalling $51,596.02. Following the completion of the sale, the chief operating officer now directly owns 2,032 shares of the company's stock, valued at $56,306.72. Learn More on Peter Stegagno's trading history.
Are insiders buying or selling shares of Sanuwave Health?: In the last twelve months, insiders at the sold shares 2 times. They sold a total of 5,501 shares worth more than $166,588.42. The most recent insider tranaction occured on June, 5th when COO Peter Stegagno sold 1,862 shares worth more than $51,596.02. Insiders at Sanuwave Health own 14.9% of the company. Learn More about insider trades at Sanuwave Health.
Information on this page was last updated on 6/5/2025.

Peter Stegagno Insider Trading History at Sanuwave Health

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/5/2025	Sell	1,862	$27.71	$51,596.02	2,032

Peter Stegagno Buying and Selling Activity at Sanuwave Health

Sanuwave Health Company Overview

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Today's Range

Now: $33.90

$32.50

$34.65

50 Day Range

MA: $32.73

$26.41

$40.82

2 Week Range

Now: $33.90

$18.50

$46.58

Volume

110,761 shs

Average Volume

89,496 shs

Market Capitalization

$290.86 million

P/E Ratio

N/A

Dividend Yield